Načítá se...
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with (89)Zr in Human Lymphoma Xenografts
Radioimmunotherapies with monoclonal antibodies to the B-lymphocyte antigen 20 (CD20) are effective treatments for B-cell lymphomas, but U.S. Food and Drug Administration–approved radioimmunotherapies exclusively use radiolabeled murine antibodies, potentially limiting redosing. The Food and Drug Ad...
Uloženo v:
| Vydáno v: | J Nucl Med |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Society of Nuclear Medicine
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6071500/ https://ncbi.nlm.nih.gov/pubmed/29348316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.117.203299 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|